Exon 45 and Exon 44 Skipping Program Updates As an early investor in Entrada Therapeutics, we are pleased to share updates on their Exon 45 and Exon 44 skipping programs […]
Duchenne muscular dystrophy research update Members of the CureDuchenne team recently attended the 31st World Muscle Society (WMS) Congress, where we spent a productive week connecting with researchers, clinicians, pharmaceutical […]
Capricor Therapeutics presented data from HOPE-3 Open Label Extension study at the 2026 World Muscle Society Congress indicating that deramiocel treatment is associated with a slower decline in upper limb […]
ELEVIDYS Data Read the press release and letter to the community:
Secretome Therapeutics has initiated an open label phase 2 study to evaluate the safety and potential skeletal muscle and cardiac effects of STM-01, an investigational cell therapy derived from cardiac progenitor cells. […]
Dyne Therapeutics: FORZETTO Explained: Understanding the Phase 3 Trial of Zeleciment Rostudirsen (DYNE-251) for Duchenne Watch HERE
When a child is diagnosed with Duchenne muscular dystrophy, one of the most important parts of care is having a healthcare team that understands the disease. Physical therapy plays an essential role in […]
Capricor Therapeutics recently shared an update on the FDA review of their investigational therapy, deramiocel. The company shared that the Biologics License Application (BLA) for deramiocel remains under FDA review […]
Watch our webinar (in English and Spanish) with helpful insights on who is eligible, common school supports, transition planning, and how to build a strong partnership with your child’s school. […]
